Colon Cancer - Phase III C-08 Study Of Avastin In Early-Stage Colon Cancer Did Not - Medical News Today
Phase III C-08 Study Of Avastin In Early-Stage Colon Cancer Did Not - Medical News Today
Genentech, Inc. announced that a Phase III study of Avastin (bevacizumab) plus chemotherapy following surgery in patients with early-stage (adjuvant) colon cancer (NSABP C-08) did not meet its primary endpoint of reducing the risk of cancer
Phase III C-08 Study Of Avastin In Early-stage Colon Cancer Does Not - Medical News Today
Roche announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy (FOLFOX) for the treatment of colon cancer immediately following surgery (adjuvant therapy) compared to chemotherapy alone. The
Find out how patients are getting back on their feet faster after - WQAD
More than 110 thousand people will be diagnosed with colon cancer this year, the second leading cause of cancer-related deaths in the U-S. Traditionally, the treatment plan includes surgery, staples and a slow recovery. Now doctors are using a
Avastin Falls Short in Test as Colon Cancer Medicine - New York Times
In results from a widely watched clinical trial, the drug Avastin failed to show a significant effect on preventing the recurrence of colon cancer , the drug s maker, Genentech, said early Wednesday. Although Avastin is already a best-selling
Avastin Setback For Roche - Forbes
Roche , the Swiss drugmaker that last February bought U.S. firm Genentech, saw its stock valuation being reduced on Wednesday after an early-stage colon cancer drug developed by its American partner missed a development milestone. Shares of Roche